|
|
|
NAFLD
https://www.ncbi.nlm.nih.gov/pubmed/28214020
Mosca A, Nobili V, De Vito R, Crudele A, Scorletti E, Villani A, Alisi A, Byrne CD.
J Hepatol. 2017 Feb 6. pii: S0168-8278(17)30002-8
Abstract
BACKGROUND & AIMS:
Recent research has suggested that dietary fructose intake may increase serum uric acid (UA) concentrations. Both UA concentration and fructose consumption maybe also increase in NAFLD. It is not known whether dietary fructose consumption and UA concentration are independently associated with non-alcoholic steatohepatitis (NASH). Our aim was to investigate the factors associated with NASH in children and adolescents with proven NAFLD, and to test whether UA concentrations and fructose consumption are independently associated with NASH.
METHODS:
https://www.ncbi.nlm.nih.gov/pubmed/31834057 NAFLD
Eur J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1097/MEG.0000000000001608. [Epub ahead of print]
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Elkabany ZA1, Hamza RT1, Ismail EAR2, Elsharkawy A3, Yosry A3, Musa S3, Khalaf MA1, Elgawesh RM1, Esmat G3.
Abstract
BACKGROUND:
Obesity is associated with an increased risk of nonalcoholic fatty liver disease (NAFLD). Visfatin is an adipokine produced by visceral fat tissue and liver cells. Transient elastography with controlled attenuation parameter (CAP) noninvasively assesses liver fibrosis and steatosis.
AIM:
https://www.ncbi.nlm.nih.gov/pubmed/31657145 NAFLD
Pediatr Obes. 2019 Oct 27. doi: 10.1111/ijpo.12581. [Epub ahead of print]
Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease.
Seth A1, Orkin S2, Yodoshi T2, Liu C3, Fei L3, Hardy J2, Trout AT4, Arce Clachar AC2, Bramlage K2, Xanthakos S2, Mouzaki M2.
Abstract
BACKGROUND:
Paediatric non-alcoholic fatty liver disease (NAFLD) is highly prevalent among children with obesity. The primary objective of this study was determining whether obesity severity is associated with NAFLD severity. By using paediatric classifications for severe obesity, clinicians may be able to better risk stratify patients, which in turn would guide more effective management and treatment.
METHODS:
http://www.ncbi.nlm.nih.gov/pubmed/24552673
Tutar O, Beşer ÖF, Adaletli I, Tunc N, Gulcu D, Kantarci F, Mihmanli I, Cokugras FC, Kutlu T, Ozbay G, Erkan T. Shear wave elastography in the evaluation of liver fibrosis in children. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6): 750-5.
Abstract
BACKGROUND:
Shear-wave elastography (SWE) is a novel non-invasive method that involves application of local mechanical compression on soft tissue using focused ultrasonography and acquiring strain images that show tissue response. In this study, our goal was to assess the performance of SWE in the staging of liver fibrosis in children with chronic liver disease.
METHODS:
https://pubmed.ncbi.nlm.nih.gov/35444966/ NAFLD
Front Pediatr. 2022 Apr 4;10:846273.
doi: 10.3389/fped.2022.846273. eCollection 2022.
Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children
Yiyoung Kwon 1, Eun Sil Kim 1, Yon Ho Choe 1, Mi Jin Kim 1
Abstract
Background: The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from isolated hepatic steatosis to non-alcoholic steatohepatitis to fibrosis. We aimed to introduce useful biomarkers released during liver inflammation and fibrogenesis that are easy to use in outpatient clinic and adjust to children to evaluate each NAFLD stage without biopsy.
https://www.ncbi.nlm.nih.gov/pubmed/30588836 NAFLD
Antioxid Redox Signal. 2018 Dec 27. doi: 10.1089/ars.2018.7704. [Epub ahead of print]
The antioxidant effects of Hydroxytyrosol and Vitamin E on pediatric NAFLD, in a clinical trial: a new treatment?
Nobili V1, Alisi A2, Mosca A3, Crudele A4, Zaffina S5, Denaro M6, Smeriglio A7, Trombetta D8.
Abstract
TRIAL DESIGN:
https://pubmed.ncbi.nlm.nih.gov/35758473/ NAFLD
J Pediatr Gastroenterol Nutr. 2022 Jun 27.
doi: 10.1097/MPG.0000000000003537.Online ahead of print.
The benefit of probiotics in pediatric non-alcoholic fatty liver disease: a meta-analysis of randomized control trials
Νikolaos Gkiourtzis 1 2, Georgios Kalopitas 3, Andreas Vadarlis 3 4, Dimitra Rafailia Bakaloudi 2, Georgios Dionysopoulos 2, Evangelia Karanika 2, Eirini Tsekitsidi 2, Michail Chourdakis 2
Abstract
Objectives: We conducted a systematic review and meta-analysis to provide a summary of the current literature about the efficacy of probiotics in pediatric non-alcoholic fatty liver disease (NAFLD).
https://www.ncbi.nlm.nih.gov/pubmed/32223545 NAFLD
Paediatr Int Child Health. 2020 Mar 30:1-5. doi: 10.1080/20469047.2020.1747002. [Epub ahead of print]
The change in prevalence of suspected non-alcoholic fatty liver disease in Korean adolescents from 2001 to 2017.
Park SH1, Park YE1, Lee J1, Choi JH1, Heo NY1, Park J1, Kim TO1, Hwang JS1, Kim E1, Oh EH1, Jang HJ1, Park HY2, Kim HK1.
Abstract
Naim Alkhouri, Sana Mansoor, Paola Giammaria, Rocio Lopez, Valerio Nobili,
Gastroenterology 2014 May; 146 (7): s 40
http://www.gastrojournal.org/article/S0016-5085%2814%2960040-8/pdf
Background:
Noninvasive hepatic fibrosis scores that predict the presence of advanced fibrosis have been developed and validated in adult patients with NAFLD. There is an urgent need to test and develop similar scores in children with NAFLD. The aim of our study was to assess the utility of commonly used adult fibrosis scores in pediatric NAFLD and to develop a pediatric specific fibrosis score that can predict advanced fibrosis.
Methods:
https://www.ncbi.nlm.nih.gov/pubmed/31428049 NAFLD
Front Endocrinol (Lausanne). 2019 Aug 2;10:514. doi: 10.3389/fendo.2019.00514. eCollection 2019.
The Liver in Children With Metabolic Syndrome.
D'Adamo E1, Castorani V2, Nobili V3,4.
Abstract
SMS requests to
9224791366
Ask The Expert
Pediatric Liver Specialists in India
Centres offering Genetic Testing for Pediatric Liver Diseases
Financial Aid Offered by Trusts
